Abstract

Granulosa cell tumors of the ovary (GCT) are the predominant type of ovarian sex cord/stromal tumor. Although prognosis is generally favorable, the outcome for advanced and recurrent GCT is poor. A better understanding of the molecular pathogenesis of GCT is critical to developing effective therapeutic strategies. Here we have examined the potential role of the runt-related transcription factor RUNX3. There are only two GCT cell lines available. While RUNX3 is silenced in the GCT cell line KGN cells, it is highly expressed in another GCT cell line, COV434 cells. Re-expression of RUNX3 promotes proliferation, anchorage-independent growth, and motility in KGN cells in vitro and tumor formation in mice in vivo. Furthermore, expression of a dominant negative form of RUNX3 decreases proliferation of COV434 cells. To address a potential mechanism of action, we examined expression of cyclin D2 and the CDK inhibitor p27Kip1, two cell cycle regulators known to be critical determinants of GCT cell proliferation. We found that RUNX3 upregulates the expression of cyclin D2 at the mRNA and protein level, and decreases the level of the p27Kip1 protein, but not p27Kip1 mRNA. In conclusion, we demonstrate that RUNX proteins are expressed in GCT cell lines and human GCT specimens, albeit at variable levels, and RUNX3 may play an oncogenic role in a subset of GCTs.

Highlights

  • Granulosa cell tumors of the ovary (GCT) are the predominant type of ovarian sex cord/stromal tumors that account for 3–5% of all malignant ovarian tumors [1]

  • We examined the expression of RUNX proteins and CBFβ in human GCT cell lines and determined that RUNX3 promotes the tumorigenic phenotypes in GCT cells

  • To determine whether RUNX proteins are involved in pathogenesis of GCT, we first examined their expression in the two GCT cell lines and an immortalized human granulosa cell line (SVOG)

Read more

Summary

Introduction

Granulosa cell tumors of the ovary (GCT) are the predominant type of ovarian sex cord/stromal tumors that account for 3–5% of all malignant ovarian tumors [1]. The rate of GCT recurrence has been reported to be 10–28% and approximately 80% of patients who relapse will succumb to disease [3,4,5]. Surgery is the predominant form of treatment for patients with early stage disease, and chemotherapy is used to treat recurrent or metastatic disease [1,3,4]. There is no standard treatment for relapsed GCT patients. GCT is believed to arise from proliferating granulosa cells of the periovulatory follicle. It is classified into two distinct forms: Adult GCT (AGCT)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call